Dynavax (NASDAQ: DVAX) reported Q1 EPS of ($0.07), $0.05 worse than the analyst estimate of ($0.02). Revenue for the quarter came in at $50.79 million versus the consensus estimate of $55.68 million.

GUIDANCE:

Dynavax sees FY2024 revenue of $265-280 million, versus the consensus of $288 million, including approximately $3 million in ex-U.S. sales through commercialization partnership in Germany
HEPLISAV-B gross margin of approximately 80%
Research and development expenses between approximately $60 - $75 million
Selling, general and administrative expenses between approximately $160 - $180 million
Expect cash, cash equivalents and marketable securities to be higher as of December 31, 2024, compared to December 31, 2023

For earnings history and earnings-related data on Dynavax (DVAX) click here.